Physician profile
Robert Dettmer
NPI 1679648281
$23,375.99
in general payments reported to CMS, 2019-2025
43 companies · $4,074 in 2025
The $4,074 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,690 · 2020: $4,533 · 2021: $2,760 · 2022: $2,915 · 2023: $3,045 · 2024: $3,359 · 2025: $4,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $18.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,460.01 |
| Education | $18.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,106.44 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,072.14 | 2019-2025 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $2,810.95 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $1,675.68 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,577.11 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $1,352.85 | 2019-2025 | |
| Gilead Sciences, INC. | $1,310.29 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $764.16 | 2019-2024 | Linzess |
| Celgene Corporation | $698.38 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $556.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $516.97 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $463.38 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $417.48 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $397.88 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $304.73 | 2020-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $275.56 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $245.56 | 2020-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $205.86 | 2024-2025 | Iqirvo |
| Ucb, INC. | $201.03 | 2019 | |
| Ferring Pharmaceuticals INC. | $200.02 | 2019-2024 | Rebyota, Clenpiq |
| Merck Sharp & Dohme LLC | $166.14 | 2019-2024 | Dificid |
| Allergan, INC. | $159.20 | 2019-2020 | |
| Exact Sciences Corporation | $150.98 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $91.39 | 2023-2024 | Cre Pro |
| Amgen INC. | $87.29 | 2023-2025 | Avsola, Amjevita, Uplizna |
| Intercept Pharmaceuticals, INC. | $70.21 | 2020-2024 | |
| Vivus LLC | $63.85 | 2025 | Pancreaze |
| Lucid Diagnostics INC. | $45.39 | 2023 | |
| Concordia Pharmaceuticals INC. | $44.94 | 2019 | |
| Intra-Sana Laboratories | $40.78 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Novo Nordisk INC | $39.73 | 2025 | Wegovy |
| Endogastric Solutions, INC | $35.64 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $30.86 | 2023 | Fujifilm |
| Evoke Pharma, INC. | $30.33 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $28.51 | 2024 | Dupixent |
| Echosens North America, INC. | $24.32 | 2023 | Fibroscan |
| Alnylam Pharmaceuticals INC. | $24.18 | 2022 | |
| Biocon Biologics INC | $21.20 | 2025 | Yesintek |
| Alfasigma USA, INC. | $19.52 | 2020 | |
| Celltrion USA INC. | $18.63 | 2024 | Zymfentra |
| Endo Pharmaceuticals INC. | $16.96 | 2019 | |
| Medtronic Vascular, INC. | $13.32 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$35,814.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dettmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.